AVI's Partner Global Therapeutics Initiates Study of New Drug Eluting Stent
Posted on: Tuesday, 11 November 2008, 09:00 CST
AVI BioPharma, a developer of RNA-based drugs, has announced that its partner Global Therapeutics, a Cook Medical company, has initiated a clinical trial of a drug eluting stent that uses a peptide-conjugated morpholino phosphorodiamidate oligomer-based RNA therapeutic agent aimed at silencing C-MYC, one of the genes responsible for causing arteries to reclose after stenting.
The feasibility study is a prospective, open-label, multi-center trial being performed in Germany. As many as 90 patients will be enrolled and all subjects will undergo clinical follow-up at 30 days and six months. Angiographic results will be reported at six months using quantitative coronary angioplasty and intravascular ultrasound.
The primary endpoint for the study is composite safety - major adverse cardiac events - at 30 days. Other endpoints include performance criteria such as in-stent and in-segment late loss, binary restenosis and target lesion revascularization. Data from the study will be compared to historical controls of both bare and drug eluting stents.
Joseph Horn, president of Global Therapeutics, said: "Based on our preliminary work with this class of drug, the delivery system, and the stent platform, we are extremely excited to begin what we hope will be a groundbreaking trial that advances the science of treating coronary artery disease beyond what current technologies can achieve. With the help of our European colleagues, we eagerly anticipate a successful outcome to this landmark trial in 2009."
Source: Datamonitor
Related Articles
- QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System
- Affymetrix Announces New Cost-Effective Product for Standardizing Drug Metabolism Studies
- The Multiple Myeloma Research Consortium (MMRC) Announces Initiation of First Four-Drug Combination Study to Treat Newly Diagnosed Multiple Myeloma Patients
- Drug Trials Go Unwatched, Study Says
- OSI Pharmaceuticals Announces Positive Results From a Metformin Drug Interaction Study With Its DP-IV Inhibitor, PSN9301
- Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
- Samaritan Kicks Off Second HIV Phase II Monotherapy Trial to Further Study Oral HIV Entry Inhibitor Drug SP-01A
- Pregnant Women Not Using Acne Drug Properly: Study
- Guidant Begins Enrollment in European Drug Eluting Stent Study; Data From Study Will Support Launch of XIENCE V Coronary Stent System Outside the United States
- Encysive Drug Meets Study Endpoint
 |
 |
User Comments (0)
RSS Feeds